Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0XBPWS |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | FL1 |
|||||
| Organization | The Finsen Laboratory.; Biotech Research & Innovation Centre (BRIC), Faculty of Health and Medical Sciences, University of Copenhagen. |
|||||
| Synonyms |
FL1
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Murine lgG1 |
|||||
| Antigen Name | Urokinase-type plasminogen activator (Plau) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
FL1-PNU [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.005 nM
|
High uPAR expression (uPAR +++) | ||
| Method Description |
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.02 nM
|
High uPAR expression (uPAR +++) | ||
| Method Description |
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KPC2 cells | Mus musculus | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.03 nM
|
High uPAR expression (uPAR +++) | ||
| Method Description |
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KPC1 cells | Mus musculus | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.05 nM
|
Moderate uPAR expression (uPAR++) | ||
| Method Description |
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.08 nM
|
High uPAR expression (uPAR +++) | ||
| Method Description |
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | AsPc1 cells | CVCL_0152 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.3 nM
|
Moderate uPAR expression (uPAR++) | ||
| Method Description |
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | MIA PaCa-2 cells | CVCL_0428 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
12 nM
|
Negative uPAR expression (uPAR-) | ||
| Method Description |
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KPC2 cells (uPAR KO) | Mus musculus | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
17 nM
|
Negative uPAR expression (uPAR-) | ||
| Method Description |
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KPC1 cells (uPAR KO) | Mus musculus | ||
References
